Ember Therapeutics Angles For Lead In ‘Brown Fat’ Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Ember’s co-founder Bruce Spiegelman explained in the Banting Lecture at the American Diabetes Association earlier in June how his lab at Harvard discovered the hormone irisin, which appears to be a key regulator of fat metabolism and may be responsible for beneficial functions of ‘brown’ fat.
You may also be interested in...
Beta/Islet Cell Regeneration Leads Diabetes Deal-Making This Decade
A review of deal-making in the diabetes space since 2010 finds deals around technology to regenerate pancreatic beta cells and/or islet cells as the hottest mechanism of action. Thirteen deals in this area out-number the combined deals involving the DPP-4, SGLT-2 and GLP-1 mechanisms during that period.
Insulin The Focus At ADA 2012, But Don’t Forget GLP-1s And SGLT-2s
In anticipation of the American Diabetes Conference of 2012, analysts take a look at several categories of drugs that will be playing a major role in the future of diabetes care.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.